Immunitybio Stock Performance

IBRX Stock  USD 10.44  0.66  6.75%   
Immunitybio holds a performance score of 24 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -0.0345, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Immunitybio are expected to decrease at a much lower rate. During the bear market, Immunitybio is likely to outperform the market. Use Immunitybio maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immunitybio.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Immunitybio are ranked lower than 24 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Immunitybio showed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
6.75
Five Day Return
(14.22)
Year To Date Return
416.83
Ten Year Return
33.67
All Time Return
(69.86)
1
Acquisition by Richard Adcock of 34483 shares of Immunitybio subject to Rule 16b-3
01/05/2026
2
Assessing ImmunityBio After Its Recent Share Price Surge and DCF Valuation
01/14/2026
3
ImmunityBio Approval And Trial Updates Spark Valuation Debate For Investors
01/21/2026
4
ImmunityBio Sheds 4 percent on Profit-Taking After 14-Day Run
01/28/2026
5
ImmunityBios Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade
02/09/2026
6
ImmunityBio Advances Chemotherapy Free Immunotherapies And Faces Key Investor Tests
02/11/2026
7
Assessing ImmunityBio Valuation After Anktiva Progress And Upcoming 2026 ASCO Presentation
02/13/2026
8
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investme...
02/17/2026
9
Why ImmunityBio Stock Is Soaring Today
02/18/2026
10
Insiders Favor These 3 Leading Growth Companies
02/19/2026
11
INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
02/20/2026
12
Why ImmunityBio Is Up 65.3 percent After ANKTIVAs European Approval And New Regional Partnerships
02/24/2026
Begin Period Cash Flow143.9 M
Total Cashflows From Investing Activities-149.8 M

Immunitybio Relative Risk vs. Return Landscape

If you would invest  209.00  in Immunitybio on December 2, 2025 and sell it today you would earn a total of  835.00  from holding Immunitybio or generate 399.52% return on investment over 90 days. Immunitybio is currently generating 3.0763% in daily expected returns and assumes 10.1644% risk (volatility on return distribution) over the 90 days horizon. In different words, 91% of stocks are less volatile than Immunitybio, and 38% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Immunitybio is expected to generate 13.42 times more return on investment than the market. However, the company is 13.42 times more volatile than its market benchmark. It trades about 0.3 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Immunitybio Target Price Odds to finish over Current Price

The tendency of Immunitybio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 10.44 90 days 10.44 
about 1.64
Based on a normal probability distribution, the odds of Immunitybio to move above the current price in 90 days from now is about 1.64 (This Immunitybio probability density function shows the probability of Immunitybio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Immunitybio has a beta of -0.0345. This usually indicates as returns on the benchmark increase, returns on holding Immunitybio are expected to decrease at a much lower rate. During a bear market, however, Immunitybio is likely to outperform the market. In addition to that Immunitybio has an alpha of 2.8561, implying that it can generate a 2.86 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Immunitybio Price Density   
       Price  

Predictive Modules for Immunitybio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunitybio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.428.3818.54
Details
Intrinsic
Valuation
LowRealHigh
0.5110.1520.31
Details
Naive
Forecast
LowNextHigh
2.3812.5422.71
Details
5 Analysts
Consensus
LowTargetHigh
12.2913.5014.99
Details

Immunitybio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunitybio is not an exception. The market had few large corrections towards the Immunitybio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunitybio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunitybio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
2.86
β
Beta against Dow Jones-0.03
σ
Overall volatility
2.76
Ir
Information ratio 0.28

Immunitybio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunitybio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunitybio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Immunitybio is way too risky over 90 days horizon
Immunitybio appears to be risky and price may revert if volatility continues
Immunitybio has high likelihood to experience some financial distress in the next 2 years
Immunitybio currently holds 878.12 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 113.29 M. Net Loss for the year was (351.4 M) with profit before overhead, payroll, taxes, and interest of 112.53 M.
Immunitybio currently holds about 82.94 M in cash with (304.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Roughly 64.0% of the company shares are held by company insiders
Latest headline from simplywall.st: Why ImmunityBio Is Up 65.3 percent After ANKTIVAs European Approval And New Regional Partnerships

Immunitybio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunitybio Stock often depends not only on the future outlook of the current and potential Immunitybio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunitybio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding919.9 M
Cash And Short Term Investments242.8 M

Immunitybio Fundamentals Growth

Immunitybio Stock prices reflect investors' perceptions of the future prospects and financial health of Immunitybio, and Immunitybio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunitybio Stock performance.

About Immunitybio Performance

Evaluating Immunitybio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunitybio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunitybio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 396.99  352.88 
Return On Tangible Assets(0.72)(0.76)
Return On Capital Employed(0.58)(0.61)
Return On Assets(0.70)(0.74)
Return On Equity 0.70  0.74 

Things to note about Immunitybio performance evaluation

Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Immunitybio is way too risky over 90 days horizon
Immunitybio appears to be risky and price may revert if volatility continues
Immunitybio has high likelihood to experience some financial distress in the next 2 years
Immunitybio currently holds 878.12 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity.
The entity reported the previous year's revenue of 113.29 M. Net Loss for the year was (351.4 M) with profit before overhead, payroll, taxes, and interest of 112.53 M.
Immunitybio currently holds about 82.94 M in cash with (304.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Roughly 64.0% of the company shares are held by company insiders
Latest headline from simplywall.st: Why ImmunityBio Is Up 65.3 percent After ANKTIVAs European Approval And New Regional Partnerships
Evaluating Immunitybio's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Immunitybio's stock performance include:
  • Analyzing Immunitybio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunitybio's stock is overvalued or undervalued compared to its peers.
  • Examining Immunitybio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Immunitybio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunitybio's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Immunitybio's stock. These opinions can provide insight into Immunitybio's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Immunitybio's stock performance is not an exact science, and many factors can impact Immunitybio's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.